Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.

Name: Kaimen Rigor review — Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
Item: Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
Rating: 59
Author: Alpha1

Liu L, Ke W, Li H, Li F, Fan G, Kuang J, Ma J, Zhang X, Ji B, Li S, Du Y, Xue Y, Lyu Z, Gao L, Qu S, Shi Y, Yan L, Deng W, Xu C, Dai P, Xu L, Liu J, Wan X, Wei G, Yu S, Hong S, Zhang P, Huang Z, Cao X, Liao Z, Xiao H, Mu Y, Handelsman Y, Li Y

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2★ (Weak), 0 critical, 4 high issues for “Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.

Read full text (PMC)

DOI

10.1136/bmj-2024-080122

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/52badf78-74b2-4b35-a3aa-07343a728e6e" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/52badf78-74b2-4b35-a3aa-07343a728e6e/badge" alt="Kaimen Rigor review — 2★ (Weak), 0 critical, 4 high issues for “Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e591025bcd5bf273aff9e5214f271508ab52162ea10c2d0c4b7ebccaddaf6ba7

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.

Paper source

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 49 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is HbA1c <7.0% at week 48, which is a surrogate biomarker for long-term clinical outcomes (microvascular and macrovascular complications). The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking HbA1c reduction to the specific clinical outcomes in this population. Although HbA1c is a widely accepted surrogate, the manuscript does not provide the required validation link.
“The primary outcome was the percentage of participants achieving HbA 1c <7.0% at week 48 after SIIT.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is the proportion achieving HbA1c <7.0%: 80% in the linagliptin plus metformin group vs 60% in control (absolute difference 20%, OR 2.78). While statistically significant, the clinical meaningfulness is not explicitly anchored to a minimal clinically important difference or long-term complication risk reduction. The effect is presented as a positive result without explicit anchor to clinical meaningfulness beyond statistical significance.
“80% (78/97), 72% (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieved HbA 1c <7.0%, compared with 60% (56/93) in the control group (P=0.02 overall; P=0.003 for linagliptin plus…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 204DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported multicentre randomised controlled trial with a clear scientific premise, adequate ethical approvals, and detailed reporting of biological variables and key resources. The main weaknesses are incomplete descriptions of randomization and blinding, a vague data availability statement, and minor internal inconsistencies in reporting (rounding and terminology).

Both reviewers independently classified the study as interventional and agreed on all eight dimension statuses, with minor divergence on sub-criteria (power analysis, demographics, repository/code applicability) that did not change the overall statuses. The statistics verification recomputed 4 reported tests, all consistent; the citation check found no retracted or unresolved references; the copyedit and integrity blocks flagged minor wording and rounding issues.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Methods and results do not matchAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

2 findings · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions6 pass · 2 warn

The introduction cites the International Diabetes Federation prevalence data, the legacy effect, the UK Prospective Diabetes Study, and prior SIIT studies, acknowledging both benefits and the decline in remission over time. The rationale for the intense simplified strategy is clearly articulated, and the hypothesis follows logically from the cited evidence. Limitations of prior research (e.g., declining remission rates) are explicitly addressed as the motivation for the study.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“As discovered recently by the 24 year follow-up of the UK Prospective Diabetes Study, early intensive glycaemic control provides a near lifelong reduction in the risk of death and of microvascular and macrovascular complications.”

Introduction ¶1Find in source

“This provides a rationale for investigating whether simplified oral regimens subsequent to SIIT could help to maintain the good glycaemic control induced by SIIT by persistently avoiding the detrimental effects of glucotoxicity and circumventing the disadvantages of intricate glucose lowering regimens.”

Introduction ¶4Find in source

“Nevertheless, the remission rate declined over time, from 70% immediately after SIIT to roughly 50% at the end of the first year and around 40% at the end of the second year.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on SIIT and the legacy effect, and provides a logical rationale for the intense simplified strategy.

Evidence

Introduction ¶1Find in source

“We hypothesised that this strategy could improve glycaemic control and preserve β cell function in patients with newly diagnosed type 2 diabetes and severe hyperglycaemia.”

Introduction ¶4Find in source

“Nevertheless, the remission rate declined over time, from 70% immediately after SIIT to roughly 50% at the end of the first year and around 40% at the end of the second year.”

Introduction ¶3Find in source

Randomization used sealed envelopes prepared by a statistician, but the method of sequence generation (e.g., random number generator) is not stated, and allocation concealment is not fully described. The trial is open-label with no blinding of participants or investigators, though the rationale is partially addressed in the limitations. The power analysis is reported with a type I error of 2.5% one-sided, but the sample size calculation appears to use a one-sided test while the primary analysis uses two-sided tests, which is a minor inconsistency. Inclusion/exclusion criteria are well-defined, and the analysis population (full analysis set, per protocol) is pre-specified. Outlier handling is not explicitly described, but missing data handling via multiple imputation is reported.

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The trial design is generally sound with clear inclusion/exclusion criteria and a pre-specified analysis population, but randomization and blinding are inadequately described, and the power analysis has a minor inconsistency.

Evidence

“A statistician not involved in the study encoded and prepared random envelopes, which were then distributed to each centre and stored by the file administrator.”

MethodsFind in source

“This is an open label, nationwide, multicentre, randomised controlled trial conducted across 15 centres in China.”

MethodsFind in source

“This calculation assumed that 75% of participants in the intervention group and 55% in the control group would achieve this endpoint with a type I error of 2.5% in the one sided test.”

Statistical analysisFind in source

WARNReviewer 2· 85% conf

The study design is generally sound with clear inclusion/exclusion criteria and a pre-specified analysis population, but the randomization method is inadequately described and blinding is absent (open-label).

Evidence

“A statistician not involved in the study encoded and prepared random envelopes, which were then distributed to each centre and stored by the file administrator.”

MethodsFind in source

“This is an open label, nationwide, multicentre, randomised controlled trial conducted across 15 centres in China.”

MethodsFind in source

“Sample size estimation suggested that 89 participants per group could provide 80% power to detect a 20% higher probability of achieving HbA 1c <7.0% in the linagliptin plus metformin group versus the control group at week 48.”

Statistical analysisFind in source

Sex is reported for all participants (75% male, 25% female), and age, BMI, and health status are reported in baseline characteristics. Since both sexes are enrolled, a scientific justification for single-sex is not applicable. Demographics include age, sex, and disease duration, but race/ethnicity is not reported (though the study is in China). Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and health status, with demographics adequately described.

Evidence

paraphrase[Table 1]

“Gender: Male 75 74 71 83 0.27 | Female 28 29 32 20”

“The participants had an average age of 46.8 (standard deviation (SD) 11.2) years, a mean body mass index of 25.8 (2.9)”

ResultsFind in source

“Among the randomised participants, 75% (311/412) had a disease duration of less than six months and 25% (101/412) had a duration of six months or more”

ResultsFind in source

PASSReviewer 2· 90% conf

Biological variables are well reported: sex, age, BMI, and health status are provided for the study population.

Evidence

paraphrase[Table 1]

“Gender: Male 75 74 71 83 0.27 | Female 28 29 32 20”

“The participants had an average age of 46.8 (standard deviation (SD) 11.2) years, a mean body mass index of 25.8 (2.9)”

ResultsFind in source

The study was approved by the research ethics board of First Affiliated Hospital of Sun Yat-sen University (protocol number 2016-146). Written informed consent was obtained from all participants. The trial followed the Declaration of Helsinki and Good Clinical Practice guidelines. All applicable criteria are met.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are adequately reported with a named ethics board, informed consent, and regulatory compliance.

Evidence

“This study was approved by the research ethics board of First Affiliated Hospital of Sun Yat-sen University (2016-146).”

EthicsFind in source

“Written informed consent was obtained from all participants.”

EthicsFind in source

“The trial followed the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference for Harmonization.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics board and protocol number.

Evidence

“This study was approved by the research ethics board of First Affiliated Hospital of Sun Yat-sen University (2016-146).”

EthicsFind in source

“Written informed consent was obtained from all participants.”

EthicsFind in source

“The trial followed the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference for Harmonization.”

MethodsFind in source

The investigational products (linagliptin and metformin) are identified with brand names and manufacturers. The insulin pump and biochemical assays are identified with manufacturers. Statistical software (SPSS and GraphPad Prism) is identified with versions. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are adequately identified for a drug trial, including the investigational products and analytical software.

Evidence

“linagliptin (5 mg/day; Trajenta, Boehringer-Ingelheim, Germany) and metformin (1000 mg/day; Glucophage, Merck Serono, Switzerland)”

MethodsFind in source

“We used SPSS version 19.0 and GraphPad Prism version 9.0 for statistical procedures.”

Statistical analysisFind in source

paraphrase[Methods, Procedures and Biochemical analyses]

“continuous subcutaneous insulin infusion (MiniMed Paradigm 722 insulin pump) ... HbA 1c was measured by high performance liquid chromatography (Bio-Rad, Hercules, CA, USA).”

PASSReviewer 2· 85% conf

The investigational products (linagliptin and metformin) are identified with manufacturer and dose, and the insulin pump and laboratory equipment are named.

Evidence

“participants randomised to the linagliptin plus metformin group received both linagliptin (5 mg/day; Trajenta, Boehringer-Ingelheim, Germany) and metformin (1000 mg/day; Glucophage, Merck Serono, Switzerland)”

MethodsFind in source

“We used SPSS version 19.0 and GraphPad Prism version 9.0 for statistical procedures.”

Statistical analysisFind in source

Statistical tests are named (χ² test, Fisher's exact test, ANOVA, Kruskal-Wallis, GEE, log-rank, logistic regression). Effect sizes with confidence intervals are reported for the primary outcome. Software is identified. Data presentation includes per-group n and confidence intervals. Exact p-values are reported for many comparisons, but some are reported as thresholds (e.g., P<0.001). Assumptions are not explicitly verified, but the use of standard methods and large sample size makes this acceptable. Mathematical plausibility checks were not possible for most continuous outcomes, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical analysis is generally well reported with named tests, effect sizes with confidence intervals, and software identified, though some p-values are reported as thresholds.

Evidence

“we applied generalised linear models for continuous variables and used the χ 2 test or Fisher’s exact test for categorical variables.”

Statistical analysisFind in source

“odds ratio 2.78, 95% confidence interval (CI) 1.37 to 5.65; P=0.005”

ResultsFind in source

“P<0.001 for linagliptin plus metformin versus control”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are well described, with named tests, effect sizes with confidence intervals, and software identified. Exact p-values are reported for primary analyses.

Evidence

“For comparisons of trial outcomes among treatment groups, we applied generalised linear models for continuous variables and used the χ 2 test or Fisher’s exact test for categorical variables.”

Statistical analysisFind in source

“the linagliptin plus metformin group (odds ratio 2.78, 95% confidence interval (CI) 1.37 to 5.65; P=0.005)”

ResultsFind in source

“P=0.02 overall; P=0.003 for linagliptin plus metformin versus control”

AbstractFind in source

The data availability statement says data can be requested from the corresponding author, with de-identified participant data and other datasets available on request, but does not specify a platform, conditions, or timeframe. This is reported_but_inadequate. No repository deposit or accession numbers are provided, which is acceptable for patient-level data. No custom code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe, and no code is shared.

Evidence

“Data from this study can be requested from the corresponding author (liyb@mail.sysu.edu.cn) after its publication.”

Data availabilityFind in source

absence[Data availability statement]

No code sharing mentioned.

WARNReviewer 2· 90% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

“Data from this study can be requested from the corresponding author (liyb@mail.sysu.edu.cn) after its publication. Requests can be made for de-identified participant data, the data dictionary, and other specified datasets.”

Data availabilityFind in source

The trial is registered (NCT03194945). Funding sources and competing interests are declared. Limitations are discussed, including lack of blinding and higher-than-expected attrition. Conclusions are proportional to the evidence. Methods are detailed enough for replication. No reporting guideline (e.g., CONSORT) is explicitly mentioned, but the paper follows a structured format.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed, though no reporting guideline is mentioned.

Evidence

“Trial registration ClinicalTrials.gov NCT03194945”

AbstractFind in source

“The intervention was not blinded. Nevertheless, the fact that the primary and secondary endpoints were generated from biochemical measurements by blinded technical staff reduces potential bias.”

LimitationsFind in source

paraphrase[Funding and Competing interests]

“Funding: This study was supported by the National Key R&D Program of China (2018YFC1314100) ... Competing interests: All authors have completed the ICMJE uniform disclosure form”

PASSReviewer 2· 90% conf

The paper is transparent: trial registration is provided, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT03194945 (https://clinicaltrials.gov/ct2/show/NCT03194945)”

AbstractFind in source

“The intervention was not blinded. Nevertheless, the fact that the primary and secondary endpoints were generated from biochemical measurements by blinded technical staff reduces potential bias.”

LimitationsFind in source

paraphrase[Funding and Competing interests]

“Funding: This study was supported by the National Key R&D Program of China (2018YFC1314100)... Competing interests: All authors have completed the ICMJE uniform disclosure form...”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 34 references by DOI: 33 verified — 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but an informed reader should weigh the incomplete randomization/blinding descriptions and the vague data availability statement as minor limitations. The minor internal inconsistencies (80% vs 80.4%, 'risk ratio' vs 'odds ratio') are cosmetic and do not undermine the conclusions, but they would warrant a correction or clarification if the authors wish to maintain the highest reporting standards.

1.
HIGHreporting
In the Methods (Randomisation and masking), specify the random sequence generation method (e.g., computer-generated random numbers) and describe allocation concealment in more detail.
The current description of sealed envelopes lacks the sequence generation method, which is a CONSORT requirement and a common reviewer concern.
2.
HIGHreporting
In the Methods (Study design and participants), add a rationale for the open-label design or state why blinding was not feasible.
The open-label design is a potential source of bias, and an explicit rationale would strengthen the reporting.
3.
HIGHstatistics
In the Methods (Statistical analysis), clarify whether the sample size calculation used a one-sided or two-sided test and align it with the primary analysis.
The power analysis uses a one-sided test while the primary analysis uses two-sided tests, which is an inconsistency that could affect interpretation of the study's power.
4.
HIGHdata code
In the Data availability statement, provide a concrete access mechanism (e.g., a data access committee or a repository like Vivli) and specify a timeframe for responding to requests.
The current 'on request' statement is vague and does not meet the standard for clinical trial data sharing.
5.
MEDIUMcopyedit
In the Methods (Statistical analysis), correct the terminology from 'risk ratio' to 'odds ratio' to match the reported results.
Logistic regression yields odds ratios, and the current wording is inconsistent with the results and could confuse readers.
6.
MEDIUMcopyedit
In the Abstract and Results, standardize the rounding of the primary outcome percentage (80% vs 80.4%) to a single consistent value.
The inconsistent rounding between the abstract and results text is a minor but avoidable inconsistency.
7.
MEDIUMreporting
In the Methods or a supplementary file, include a completed CONSORT checklist and a statement of adherence to the guideline.
No reporting guideline is mentioned, and a CONSORT checklist would improve transparency and reproducibility.
8.
MEDIUMstatistics
In the Methods (Statistical analysis), explicitly state how test assumptions (normality, equal variance) were checked or why they were not.
The assumptions_verified sub-criterion is currently reported_but_inadequate, and adding this detail would strengthen the statistical reporting.
9.
MEDIUMstatistics
In the Results, report exact p-values for all comparisons where possible, rather than thresholds like P<0.001.
Threshold-only p-values are less informative and reduce transparency.
10.
MEDIUMreporting
In the Discussion, add a note on the generalizability of the findings to other ethnic populations, as the study was conducted only in China.
The lack of racial/ethnic diversity is a limitation that should be acknowledged for readers applying the results to other populations.
11.
LOWcopyedit
In the Author affiliations, correct the misspelling of 'Shenzen' to 'Shenzhen'.
This is a minor typo that should be fixed for professionalism.
12.
LOWdata code
Consider depositing the statistical analysis plan and protocol in a public repository (e.g., ClinicalTrials.gov already has the registration, but a protocol repository would be helpful).
This would enhance transparency and allow readers to verify the pre-specified analyses.

Full text (51,531 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.

Read full text (PMC)

DOI

10.1136/bmj-2024-080122

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/52badf78-74b2-4b35-a3aa-07343a728e6e" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/52badf78-74b2-4b35-a3aa-07343a728e6e/badge" alt="Kaimen Rigor review — 2★ (Weak), 0 critical, 4 high issues for “Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e591025bcd5bf273aff9e5214f271508ab52162ea10c2d0c4b7ebccaddaf6ba7

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 49 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is HbA1c <7.0% at week 48, which is a surrogate biomarker for long-term clinical outcomes (microvascular and macrovascular complications). The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking HbA1c reduction to the specific clinical outcomes in this population. Although HbA1c is a widely accepted surrogate, the manuscript does not provide the required validation link.
“The primary outcome was the percentage of participants achieving HbA 1c <7.0% at week 48 after SIIT.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is the proportion achieving HbA1c <7.0%: 80% in the linagliptin plus metformin group vs 60% in control (absolute difference 20%, OR 2.78). While statistically significant, the clinical meaningfulness is not explicitly anchored to a minimal clinically important difference or long-term complication risk reduction. The effect is presented as a positive result without explicit anchor to clinical meaningfulness beyond statistical significance.
“80% (78/97), 72% (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieved HbA 1c <7.0%, compared with 60% (56/93) in the control group (P=0.02 overall; P=0.003 for linagliptin plus…”
Find in source

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Methods and results do not matchAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

2 findings · worst medium

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions6 pass · 2 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

Introduction ¶1Find in source

Introduction ¶4Find in source

“Nevertheless, the remission rate declined over time, from 70% immediately after SIIT to roughly 50% at the end of the first year and around 40% at the end of the second year.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on SIIT and the legacy effect, and provides a logical rationale for the intense simplified strategy.

Evidence

Introduction ¶1Find in source

“We hypothesised that this strategy could improve glycaemic control and preserve β cell function in patients with newly diagnosed type 2 diabetes and severe hyperglycaemia.”

Introduction ¶4Find in source

“Nevertheless, the remission rate declined over time, from 70% immediately after SIIT to roughly 50% at the end of the first year and around 40% at the end of the second year.”

Introduction ¶3Find in source

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

Evidence

“A statistician not involved in the study encoded and prepared random envelopes, which were then distributed to each centre and stored by the file administrator.”

MethodsFind in source

“This is an open label, nationwide, multicentre, randomised controlled trial conducted across 15 centres in China.”

MethodsFind in source

“This calculation assumed that 75% of participants in the intervention group and 55% in the control group would achieve this endpoint with a type I error of 2.5% in the one sided test.”

Statistical analysisFind in source

WARNReviewer 2· 85% conf

Evidence

“A statistician not involved in the study encoded and prepared random envelopes, which were then distributed to each centre and stored by the file administrator.”

MethodsFind in source

“This is an open label, nationwide, multicentre, randomised controlled trial conducted across 15 centres in China.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and health status, with demographics adequately described.

Evidence

paraphrase[Table 1]

“Gender: Male 75 74 71 83 0.27 | Female 28 29 32 20”

“The participants had an average age of 46.8 (standard deviation (SD) 11.2) years, a mean body mass index of 25.8 (2.9)”

ResultsFind in source

“Among the randomised participants, 75% (311/412) had a disease duration of less than six months and 25% (101/412) had a duration of six months or more”

ResultsFind in source

PASSReviewer 2· 90% conf

Biological variables are well reported: sex, age, BMI, and health status are provided for the study population.

Evidence

paraphrase[Table 1]

“Gender: Male 75 74 71 83 0.27 | Female 28 29 32 20”

“The participants had an average age of 46.8 (standard deviation (SD) 11.2) years, a mean body mass index of 25.8 (2.9)”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are adequately reported with a named ethics board, informed consent, and regulatory compliance.

Evidence

“This study was approved by the research ethics board of First Affiliated Hospital of Sun Yat-sen University (2016-146).”

EthicsFind in source

“Written informed consent was obtained from all participants.”

EthicsFind in source

“The trial followed the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference for Harmonization.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics board and protocol number.

Evidence

“This study was approved by the research ethics board of First Affiliated Hospital of Sun Yat-sen University (2016-146).”

EthicsFind in source

“Written informed consent was obtained from all participants.”

EthicsFind in source

“The trial followed the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference for Harmonization.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are adequately identified for a drug trial, including the investigational products and analytical software.

Evidence

“linagliptin (5 mg/day; Trajenta, Boehringer-Ingelheim, Germany) and metformin (1000 mg/day; Glucophage, Merck Serono, Switzerland)”

MethodsFind in source

“We used SPSS version 19.0 and GraphPad Prism version 9.0 for statistical procedures.”

Statistical analysisFind in source

paraphrase[Methods, Procedures and Biochemical analyses]

“continuous subcutaneous insulin infusion (MiniMed Paradigm 722 insulin pump) ... HbA 1c was measured by high performance liquid chromatography (Bio-Rad, Hercules, CA, USA).”

PASSReviewer 2· 85% conf

The investigational products (linagliptin and metformin) are identified with manufacturer and dose, and the insulin pump and laboratory equipment are named.

Evidence

MethodsFind in source

“We used SPSS version 19.0 and GraphPad Prism version 9.0 for statistical procedures.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical analysis is generally well reported with named tests, effect sizes with confidence intervals, and software identified, though some p-values are reported as thresholds.

Evidence

“we applied generalised linear models for continuous variables and used the χ 2 test or Fisher’s exact test for categorical variables.”

Statistical analysisFind in source

“odds ratio 2.78, 95% confidence interval (CI) 1.37 to 5.65; P=0.005”

ResultsFind in source

“P<0.001 for linagliptin plus metformin versus control”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are well described, with named tests, effect sizes with confidence intervals, and software identified. Exact p-values are reported for primary analyses.

Evidence

Statistical analysisFind in source

“the linagliptin plus metformin group (odds ratio 2.78, 95% confidence interval (CI) 1.37 to 5.65; P=0.005)”

ResultsFind in source

“P=0.02 overall; P=0.003 for linagliptin plus metformin versus control”

AbstractFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe, and no code is shared.

Evidence

“Data from this study can be requested from the corresponding author (liyb@mail.sysu.edu.cn) after its publication.”

Data availabilityFind in source

absence[Data availability statement]

No code sharing mentioned.

WARNReviewer 2· 90% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed, though no reporting guideline is mentioned.

Evidence

“Trial registration ClinicalTrials.gov NCT03194945”

AbstractFind in source

“The intervention was not blinded. Nevertheless, the fact that the primary and secondary endpoints were generated from biochemical measurements by blinded technical staff reduces potential bias.”

LimitationsFind in source

paraphrase[Funding and Competing interests]

“Funding: This study was supported by the National Key R&D Program of China (2018YFC1314100) ... Competing interests: All authors have completed the ICMJE uniform disclosure form”

PASSReviewer 2· 90% conf

The paper is transparent: trial registration is provided, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT03194945 (https://clinicaltrials.gov/ct2/show/NCT03194945)”

AbstractFind in source

“The intervention was not blinded. Nevertheless, the fact that the primary and secondary endpoints were generated from biochemical measurements by blinded technical staff reduces potential bias.”

LimitationsFind in source

paraphrase[Funding and Competing interests]

“Funding: This study was supported by the National Key R&D Program of China (2018YFC1314100)... Competing interests: All authors have completed the ICMJE uniform disclosure form...”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 34 references by DOI: 33 verified — 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
In the Methods (Randomisation and masking), specify the random sequence generation method (e.g., computer-generated random numbers) and describe allocation concealment in more detail.
The current description of sealed envelopes lacks the sequence generation method, which is a CONSORT requirement and a common reviewer concern.
2.
HIGHreporting
In the Methods (Study design and participants), add a rationale for the open-label design or state why blinding was not feasible.
The open-label design is a potential source of bias, and an explicit rationale would strengthen the reporting.
3.
HIGHstatistics
In the Methods (Statistical analysis), clarify whether the sample size calculation used a one-sided or two-sided test and align it with the primary analysis.
The power analysis uses a one-sided test while the primary analysis uses two-sided tests, which is an inconsistency that could affect interpretation of the study's power.
4.
HIGHdata code
In the Data availability statement, provide a concrete access mechanism (e.g., a data access committee or a repository like Vivli) and specify a timeframe for responding to requests.
The current 'on request' statement is vague and does not meet the standard for clinical trial data sharing.
5.
MEDIUMcopyedit
In the Methods (Statistical analysis), correct the terminology from 'risk ratio' to 'odds ratio' to match the reported results.
Logistic regression yields odds ratios, and the current wording is inconsistent with the results and could confuse readers.
6.
MEDIUMcopyedit
In the Abstract and Results, standardize the rounding of the primary outcome percentage (80% vs 80.4%) to a single consistent value.
The inconsistent rounding between the abstract and results text is a minor but avoidable inconsistency.
7.
MEDIUMreporting
In the Methods or a supplementary file, include a completed CONSORT checklist and a statement of adherence to the guideline.
No reporting guideline is mentioned, and a CONSORT checklist would improve transparency and reproducibility.
8.
MEDIUMstatistics
In the Methods (Statistical analysis), explicitly state how test assumptions (normality, equal variance) were checked or why they were not.
The assumptions_verified sub-criterion is currently reported_but_inadequate, and adding this detail would strengthen the statistical reporting.
9.
MEDIUMstatistics
In the Results, report exact p-values for all comparisons where possible, rather than thresholds like P<0.001.
Threshold-only p-values are less informative and reduce transparency.
10.
MEDIUMreporting
In the Discussion, add a note on the generalizability of the findings to other ethnic populations, as the study was conducted only in China.
The lack of racial/ethnic diversity is a limitation that should be acknowledged for readers applying the results to other populations.
11.
LOWcopyedit
In the Author affiliations, correct the misspelling of 'Shenzen' to 'Shenzhen'.
This is a minor typo that should be fixed for professionalism.
12.
LOWdata code
Consider depositing the statistical analysis plan and protocol in a public repository (e.g., ClinicalTrials.gov already has the registration, but a protocol repository would be helpful).
This would enhance transparency and allow readers to verify the pre-specified analyses.

Full text (51,531 chars)Analyzed: Aug 16, 2026